What a New Systematic Review Found About NAD+ and Anti-Ageing Evidence

What Did This New NAD+ Review Actually Analyse?

Researchers Cory Gallagher and Owoturo Oluwaseun Emmanuel published a PRISMA-guided systematic review of NAD+ supplementation research in Ageing Research Reviews, an Elsevier journal covering the biology of ageing.[1] Rather than a narrative summary, the review followed a pre-specified search-and-screening protocol to identify every eligible peer-reviewed intervention study on NAD+-related compounds — administered orally or parenterally — published between January 2010 and October 2025.[1]

This is a literature synthesis, not a new clinical trial. Its value is in pooling and grading what dozens of separate research groups have already published, rather than generating new experimental data.

What Did the Rodent Studies Show?

Across the 80 rodent studies, NAD+ augmentation — whether via NAD+ itself or a precursor compound — was frequently associated with improvements in metabolic, mitochondrial, inflammatory, and functional outcomes.[1] Reported endpoints in the underlying preclinical literature span markers of mitochondrial biogenesis, tissue NAD+ content, inflammatory cytokine levels, and physical-performance measures in aged or metabolically stressed animal models.

What Did the Human Studies Show?

The 33 human intervention studies concentrated almost entirely on oral NAD+ precursors — principally NR and NMN — rather than NAD+ itself.[1] Across these trials, oral precursor supplementation consistently demonstrated biochemical target engagement: circulating or cellular NAD+-related metabolites rose in a reproducible way after dosing.[1]

In other words, the review separates two different claims that are often conflated in NAD+ marketing: raising a biomarker is not the same as demonstrating a clinical benefit, and this review found solid support for the former but inconsistent support for the latter.

Why Does the Oral-vs-Parenteral Distinction Matter?

The single most-cited limitation in this review is a gap rather than a negative result: its authors report finding no eligible outcome trials that evaluated intravenous or intramuscular NAD+ itself for anti-ageing or wellness indications.[1] Nearly all of the human clinical evidence identified concerns oral precursor compounds, which are chemically and pharmacokinetically distinct from administering the NAD+ molecule directly.

This matters because NAD+ infusions and injectables are widely marketed to consumers on the assumption that bypassing oral absorption produces a stronger or more direct effect — a claim this review found no controlled outcome-trial evidence to either confirm or refute, simply because no such trial appears to exist in the published record it screened.[1] That is a distinct, and arguably more consequential, evidence gap than the mixed outcome data for oral precursors.

How Does This Fit With Broader NAD+ Coverage in 2026?

This review lands amid growing mainstream scrutiny of NAD+ marketing claims. NPR reported in May 2026 on the gap between commercial claims for NAD+ pills and infusions and the underlying clinical evidence, while a separate Nature Aging expert review earlier in 2026 brought together more than two dozen scientists to survey NAD+'s proposed role in ageing biology without resolving the same clinical-outcome question this systematic review addresses directly.[2]

It also adds a rigorous, pooled counterpoint to the largely mechanistic framing in our own NAD+ research overview, which covers NAD+'s role as a substrate for sirtuin and PARP enzymes. That mechanistic case for why NAD+ is of research interest is well established; this systematic review is a useful reference for researchers who need to separate that mechanistic rationale from the current state of controlled outcome evidence in humans.

The distinction between mechanistic study design and pooled outcome evidence recurs across current peptide research reporting — see our recent coverage of a Copenhagen mechanistic study of MOTS-c, which similarly separates a controlled mouse-dosing arm from an observational human component rather than presenting either as proof of a human clinical outcome.

What Are the Limitations of This Review?

A systematic review is only as strong as the studies it pools. The 33 human studies varied in sample size, dosing regimen, precursor compound, and outcome measured, which limits direct comparison between them and is likely part of why the review describes clinical-outcome findings as endpoint-specific rather than convergent.[1] The absence of eligible IV/IM NAD+ outcome trials is a gap in the published literature the review screened, not evidence that such formulations are ineffective — it means the controlled research simply has not yet been done or published in a form that met the review's inclusion criteria.

The review's authors explicitly call for larger, well-designed randomised trials with longer follow-up and prespecified, clinically meaningful endpoints, particularly for parenteral NAD+ approaches — a direct acknowledgement that the current evidence base cannot yet answer the questions consumer marketing often implies are settled.[1]

What Should UK Researchers Take From This?

For researchers designing NAD+ studies, this review is a useful map of where the published evidence is solid (biomarker engagement from oral precursors, a broad but heterogeneous rodent literature) and where it is thin or absent (controlled outcome trials of injectable or intramuscular NAD+). It has no bearing on the regulatory status of research-use peptides in the UK: NAD+ remains an unlicensed research compound, and nothing here changes the position set out in our guide on whether research peptides are legal in the UK.

Velox Peptides supplies NAD+ strictly as an HPLC-verified in vitro research reagent, with batch documentation available on request and no dosing guidance of any kind.

NAD+ is referenced here for research-news context only. Where supplied by Velox Peptides, it is a research reagent, not a medicine or supplement, and has not been evaluated by the MHRA or FDA in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions